Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Open in API
Filings indexed 830 across all filing types
Latest filing 2017-04-12 Proxy Solicitation & In…
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'SCHEDULE 14A INFORMATION' and is identified as a 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934.' It includes details about the annual stockholders' meeting, voting instructions, proposals to be voted on, and board of directors' recommendations. The document is a definitive additional material related to proxy solicitation for the annual meeting. It does not contain financial statements or detailed financial analysis but rather serves as solicitation material for shareholder voting. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI).
2017-04-12 English
DEF 14A
Proxy Solicitation & Information Statement
2017-04-12 English
FORM 4
Director's Dealing
2017-03-31 English
FORM 8-K
Audit Report / Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, specifically reporting a change in the company's independent registered public accounting firm. It details the dismissal of Ernst & Young LLP and the appointment of RSM US LLP as the new auditor. The content focuses on audit firm changes, audit reports, and related disclosures, which aligns with announcements about changes in auditors or accounting firms. This type of filing is not a full audit report itself but an announcement related to audit matters. According to the filing definitions, this fits best under 'Audit Report / Information (AR)' as it pertains to audit-related information and changes in the certifying accountant. The document length (5562 characters) and detailed content support classification as AR rather than a brief announcement or regulatory filing. Therefore, the appropriate classification is AR with high confidence.
2017-03-28 English
FORM 4
Director's Dealing
2017-03-27 English
FORM 4
Director's Dealing
2017-03-24 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.